Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
SEC Accession No. 0001875620-25-000002
Filing Date
2025-07-15
Accepted
2025-07-15 11:15:44
Documents
1
Period of Report
2025-06-06

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 3/A  
1 PRIMARY DOCUMENT primary_doc.xml 3/A 8486
  Complete submission text file 0001875620-25-000002.txt   11286
Mailing Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801
Business Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801 (302) 295-3800
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Alternatives, LLC (Reporting) CIK: 0001846444 (see all company filings)

State of Incorp.: DE
Type: 3/A | Act: 34 | File No.: 001-39676 | Film No.: 251123662

Mailing Address 100 WILSON BLVD SUITE 3000 ARLINGTON VA 22209
Business Address
SANDS FRANK M. (Reporting) CIK: 0001870494 (see all company filings)

Type: 3/A | Act: 34 | File No.: 001-39676 | Film No.: 251123661

Mailing Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Life Sciences Pulse Fund II, L.P. (Reporting) CIK: 0001875620 (see all company filings)

State of Incorp.: E9
Type: 3/A | Act: 34 | File No.: 001-39676 | Film No.: 251123663